drugset / Trial / NCT01563081

Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics

NCT01563081

Phase 3 Completed 60 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety of treatment with levocetirizine oral solution in pediatric patients aged form 6 months to 2 years old with allergic rhinitis or pruritus associated with the skin diseases.

Timeline

Start
2012-04
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Levocetirizine Unknown 1.25 mg Oral

Indications